100 Clinical Results associated with SARS-CoV-2 vaccine(Vicebio)
Login to view more data
100 Translational Medicine associated with SARS-CoV-2 vaccine(Vicebio)
Login to view more data
100 Patents (Medical) associated with SARS-CoV-2 vaccine(Vicebio)
Login to view more data
1
Literatures (Medical) associated with SARS-CoV-2 vaccine(Vicebio)
01 Apr 2022·Transplant infectious disease : an official journal of the Transplantation SocietyQ4 · MEDICINE
Omicron breakthrough infection in a kidney‐transplant patient given pre‐exposition casirivimab and imdevimab monoclonal antibodies
Q4 · MEDICINE
Letter
Author: Kamar, Nassim ; Izopet, Jacques ; Gouin, Anna
A review.Despite three doses of Severe Acute Respiratory Syndrome coro- navirus 2 (SARS-CoV-2) vaccine, the humoral response and con- sequently the clin. protection remain low in immunosuppressed patients, particularly in solid-organ-transplant patients.Casirivimabandimdevimabmonoclonalantibodieshadtobegiven monthly independently of the anti-S concentration, although it was mandatorytobemeasuredjustbeforeeachinfusion.Imunosuppressedpatientswithouthumoralresponsetofull vaccination.
100 Deals associated with SARS-CoV-2 vaccine(Vicebio)
Login to view more data
R&D Status
Login to view more data
Clinical Result
Indication
Phase
Evaluation
View All Results
Study
Phase
Population
Analyzed Enrollment
Group
Results
Evaluation
Publication Date
No Data
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.